159 results
8-K/A
EX-10.2
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
statement in respect of each Product that would reasonably be expected to provide a basis for the FDA to invoke its policy with respect to “Fraud, Untrue … to any Buyer Indemnified Party to the extent resulting from the gross negligence, willful misconduct, or fraud of any Buyer Indemnified Party.
(b
8-K/A
EX-10.1
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
, including HIPAA and Section 5 of the FTC Act; (c) applicable federal, state and local fraud and abuse laws of any Governmental Authority, including
8-K
EX-2.1
ipsj0fc7
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K/A
EX-99.1
yd3qa3q9l
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
424B3
h81u2
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
y3t0rrd b0oi
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm